• Publications:
• A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non–small cell lung cancer
• Synopsis: IFCT-2101_synopsis_v2.0_20241015_IFCT.pdf